Quantapore
Quantapore is a privately held Menlo Park biotech founded in 2009 that develops nanopore-based nucleic acid sequencing technology for long-read DNA sequencing applications, though it shows no recent operational activity.
- Company typePrivate
- Founded2009
- HeadquartersMenlo Park, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Quantapore firmographics
Firmographics- Name
- Quantapore
- Website
- https://quantapore.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- Quantapore is a privately held Menlo Park biotech founded in 2009 that develops nanopore-based nucleic acid sequencing technology for long-read DNA sequencing applications, though it shows no recent operational activity.
- Ownership category
- akta.pro rank
Quantapore industry classification
Industry- Product category
- Nanopore Sequencing Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where Quantapore is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Markets served
Quantapore business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
Quantapore product offering
Product offeringCore offering
Quantapore develops proprietary nanopore-based nucleic acid sequencing technology for the reading and analysis of DNA and RNA. The company focuses on building a next-generation sequencing platform that leverages nanopore technology for genomic research and analysis applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Nanopore-based nucleic acid sequencing technology Proprietary nanopore-based sequencing platform for reading and analyzing DNA and RNA molecules, designed for genomics research laboratories and biotech research applications.
Companies that use Quantapore
Customer profileIdeal customer profiles2 records
Quantapore technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Quantapore competitors and assessment
Company assessmentEmerging players
- Singular Genomics: Developer of the G4 benchtop next-generation sequencing platform. Comparable as another emerging NGS instrumentation entrant with overlapping customer profile to Quantapore's intended market.
- Bionano Genomics: Developer of optical genome mapping and rare variant detection platforms for genomics research and clinical applications. Comparable as a non-short-read structural-variation technology competing for the same long-read-adjacent workflows.
- Element Biosciences: Developer of benchtop sequencing platforms (AVITI) aimed at lower-cost, accessible sequencing. Comparable as a well-funded emerging sequencing platform company competing to expand the installed base.
- MGI Tech (BGI Group): Sequencing and multi-omics instrumentation provider offering DNBSEQ and related platforms at aggressive price points. Comparable as a newer sequencing platform entrant attempting to undercut established western incumbents.
Broad incumbents
- Illumina: Dominant short-read sequencing incumbent with the broadest installed base and consumables franchise. Relevant as the large incumbent whose installed workflows any new nanopore platform must integrate with or displace.
- 10x Genomics: Provider of single-cell and spatial genomics tools (Chromium, Visium) that complement sequencing workflows. Comparable as a broader genomic tool platform serving overlapping research customers who would be potential Quantapore end users.
Others
- Genia Technologies: Earlier-stage nanopore sequencing developer that was acquired by Roche, illustrating both the strategic interest in nanopore IP and the typical exit trajectory for such companies. Historically directly comparable as a nanopore sequencing peer.
- Stratos Genomics: Nanopore sequencing-by-expansion technology developer acquired by Roche. Historically a direct nanopore sequencing peer and a useful comparable for IP-driven acqui-hire or M&A outcomes in this category.
Direct peers
- Pacific Biosciences (PacBio): Long-read sequencing platform company (HiFi/Sequel systems) that competes in the same third-generation sequencing category Quantapore targets. Highly relevant as a long-read alternative to nanopore chemistry.
- Oxford Nanopore Technologies: The leading commercial nanopore-based DNA/RNA sequencing platform company, offering devices such as MinION, GridION and PromethION. Directly comparable to Quantapore as a nanopore sequencing technology developer targeting similar research and clinical end-markets.
Market position
Customer concentration
Quantapore social profiles
Digital presenceQuantapore financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quantapore leadership team
Management profileNumber of profiles
Profiles2 records
Quantapore funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quantapore M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quantapore
What does Quantapore do?
Quantapore develops proprietary nanopore-based nucleic acid sequencing technology for the reading and analysis of DNA and RNA. The company focuses on building a next-generation sequencing platform that leverages nanopore technology for genomic research and analysis applications.
When was Quantapore founded?
Quantapore was founded in 2009. It employs 1 to 10 people.
Where is Quantapore based?
Quantapore is headquartered in Menlo Park, United States, in the North America region.
Who are Quantapore's main competitors?
Emerging players on record are Singular Genomics, Bionano Genomics, Element Biosciences and MGI Tech (BGI Group). Broad incumbents are Illumina and 10x Genomics. Others are Genia Technologies and Stratos Genomics. Direct peers are Pacific Biosciences (PacBio) and Oxford Nanopore Technologies.
Does Quantapore have an API?
No public API is recorded for Quantapore.
What industry is Quantapore in?
Quantapore's product category is Nanopore Sequencing Technology. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 541714 and its SIC code is 3826.